pmd-026
pmd-026: developed by 1 company · 1 clinical trial tracked. Updated within the last hour.
Lead developer: 4D Molecular Therapeutics, Inc. (FDMT)
Development Pipeline (1)
| Company | Phase |
|---|---|
| 4D Molecular Therapeutics, Inc. (FDMT) | Phase 1/Phase 2 |
Clinical Trials (1)
Ph 1/1b/2 Multicenter, Open-Label, FIH Dose Esc & Dose Exp Study to Assess Safety and Tolerability of Orally Administered PMD-026 as a Single Agent and in Combination in Patients With Metastatic or Locally Advanced (Inoperable) RSK2+ Breast Cancer
Frequently asked questions
Who is developing pmd-026?
pmd-026 is being developed by 4D Molecular Therapeutics, Inc..
How many clinical trials involve pmd-026?
BioSniper tracks 1 clinical trial involving pmd-026.
Analyze 4D Molecular Therapeutics, Inc. & pmd-026 with AI
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
- 200 free AI credits / month to run live multi-agent analysis
- Watchlist, catalyst alerts & the biotech event calendar
- Full pipeline, financials & FDA data on every company